• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

    7.050 +0.140 (+2.03%)
    Streaming Delayed Price Updated: 11:50 AM EST, Dec 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 638,798
    Open 7.150
    Bid (Size) 7.050 (400)
    Ask (Size) 7.060 (500)
    Prev. Close 6.910
    Today's Range 6.990 - 7.250
    52wk Range 3.809 - 7.200
    Shares Outstanding 55,638,166
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
    The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025. 
    Via Stocktwits
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
    Via Chartmill

    Performance

    YTD
    +46.3%
    +46.3%
    1 Month
    +41.0%
    +41.0%
    3 Month
    +46.0%
    +46.0%
    6 Month
    +46.3%
    +46.3%
    1 Year
    +46.6%
    +46.6%

    More News

    Read More
    News headline image
    Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
    Via The Motley Fool
    Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For October 29, 2025 ↗
    Via Benzinga
    Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For July 31, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 7, 2025 ↗
    Via Benzinga
    News headline image
    A Glimpse of Vanda Pharma's Earnings Potential ↗
    Via Benzinga
    News headline image
    Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    Top movers in Tuesday's session ↗
    Via Chartmill
    News headline image
    Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗
    Via Benzinga
    News headline image
    The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For February 13, 2025 ↗
    Via Benzinga
    News headline image
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
    Via Benzinga
    News headline image
    This Trex Company Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
    Via Benzinga
    News headline image
    VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock ↗
    Via Benzinga
    News headline image
    AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
    Via Benzinga
    News headline image
    Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals” ↗
    Via Stocktwits
    Topics Retirement
    News headline image
    Vanda (VNDA) Q2 Revenue Rises 4% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals ↗
    Via Benzinga

    Frequently Asked Questions

    Is Vanda Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Vanda Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Vanda Pharmaceuticals Inc. - Common Stock trade on?
    Vanda Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vanda Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Vanda Pharmaceuticals Inc. - Common Stock is VNDA on the Nasdaq Stock Market
    What is the current price of Vanda Pharmaceuticals Inc. - Common Stock?
    The current price of Vanda Pharmaceuticals Inc. - Common Stock is 7.050
    When was Vanda Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Vanda Pharmaceuticals Inc. - Common Stock was at 12/26/25 11:50 AM ET
    What is the market capitalization of Vanda Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Vanda Pharmaceuticals Inc. - Common Stock is 392.25M
    How many shares of Vanda Pharmaceuticals Inc. - Common Stock are outstanding?
    Vanda Pharmaceuticals Inc. - Common Stock has 392M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.